Geron Announces FDA Clearance to Start Clinical Trials of Its Telomerase Inhibitor Drug
The initial Phase I/II, open-label, dose-escalation trial of GRN163L will be conducted in patients with advanced CLL. The study is designed to demonstrate the safety and tolerability of GRN163L administered on a weekly intravenous dosing schedule. Pharmacokinetic and pharmacodynamic parameters will also be studied. Importantly, CLL provides a unique opportunity to measure both the magnitude and time course of telomerase inhibition in tumor cells. By serially assessing the effects on the target enzyme in CLL cells, Geron will attempt to define both a dose and a dosing interval that effectively inhibits telomerase activity. This will provide useful data for designing further clinical studies of GRN163L, including combination studies with other approved cancer therapies.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.